The influence of 5-year therapy with tibolone on the lipid profile in postmenopausal women with mild hypercholesterolemia

Gynecological Endocrinology

Volumn 18, Issue 4, 2004, Pages 227-232

  Kalogeropoulos, S ^a   Petrogiannopoulos, C ^b   Gagos, S ^c   Kampas, N ^d   Kalogeropoulos, G ^a,e  

^a IASO   (Greece)

^b RED CROSS HOSPITAL   (Greece)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^d General Hospital of Corinth   (Greece)

^e NONE   (Greece)

Author keywords

Cystic Mastopathy; Hypercholesterolemia; Lipid Profile; Menopausal Symptoms; Tibolone; Vaginal Spotting

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TIBOLONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; FEVER; FIBROCYSTIC BREAST DISEASE; GALLBLADDER DISEASE; HORMONE DEPENDENCE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; PAIN; POLYP; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIDE EFFECT; SPOTTING; TREATMENT OUTCOME; VAGINA BLEEDING;

CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; LIPOPROTEIN(A); LONGITUDINAL STUDIES; MIDDLE AGED; NORPREGNENES; POSTMENOPAUSE; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 1942537115     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590410001667238     Document Type: Article

References (34)

1. Castelo-Branco C, Vicente JJ, Figueras F, et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 2000;34:161-8
2. Egarter C, Huber J, Leikermoser R, et al. Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas 1996;23:55-62
3. Botsis D, Kassanos D, Kalogirou D, et al. Vaginal ultrasound of the endometrium in postmenopausal women with symptoms of urogenital atrophy on low-dose estrogen or tibolone treatment: a comparison. Maturitas 1997;26:57-62
4. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002;288:321-33
5. Palacios S. Tibolone: what does tissue specific activity mean? Maturitas 2001;37:159-65
6. Jensen J, Nilas L, Christansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990;12:321-31
7. Milner MH, Sinnott MM, Cooke TM, et al. A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin. Obstet Gynecol 1996;87:593-9
8. Davis SR. The effects of tibolone on mood and libido. Menopause 2002;9:162-70
9. Wu MH, Pan HA, Wang ST, et al. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. Climacteric 2001;4:314-19
10. Thiebaud D, Bigler JM, Renteria S, et al. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone. Climacteric 1998;1:202-10
11. Stevenson JC, Crook D, Codsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993;98:83-90
12. Crook D, Jackson G. Tibolone's cardiovascular risk profile. Orgyn (special issue) 1999;1:39-40
13. Castelo-Branco C, Casals E, Figueras F, et al. Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins AI and B. Menopause 1999;6:92-7
14. Koh KK, Ahn JY, Jin DK, et al. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study. Arterioscler Thromb Vasc Biol 2003;23:1889-94
15. Barnes JF, Farish E, Rankin M, et al. A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors. Atherosclerosis 2002;160:185-93
16. Lloyd G, McGing E, Cooper A, et al. A randomized placebo controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women. J Hum Hypertens 2000;14:99-104
17. Ossewaarde ME, Dallinga-Thie GM, Bots ML, et al. Treatment with hormone replacement therapy lowers remnant lipoprotein particles in healthy postmenopausal women: results from a randomized trial. Eur J Clin Invest 2003;33:376-82
18. Hanggi W, Lippyner K, Riesen W, et al. Long term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomized study. Br J Obstet Gynaecol 1997;104:708-17
19. Palomba S, Affinito P, Di Carlo C, et al. Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone, and lipid profiles. Fertil Steril 1999;72:889-95
20. Trichopoulou A, Vasilopoulou E. Mediterranean diet and longevity. Br J Nutr 2000;84(Suppl 2):S205-9
21. Adamopoulos PN, Papamechael C, Fida H, et al. Precursors of atherosclerosis in a random sample from a Hellenic population: the Athens Study. J Cardiovasc Risk 1995;2:525-31
22. Trichopoulou A, Katsouyanni K, Gnardellis C. The traditional Greek diet. Eur J Clin Nutr 1993;47(Suppl 1):S76-81
23. Albertazzi P, Di Micco R, Zanardi E. Tibolone: a review. Maturitas 1998;30:295-305
24. Simoncini T, Genazzani AR. Tibolone inhibits leukocyte adhesion molecule expression in human endothelial cells. Mol Cell Endocrinol 2000;162:87-94
25. Winkler UH, Altkemper R, Kwee B, et al. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 2000;74:10-19
26. Coelingh B. Clinical experience with tibolone, a tissue-specific hormone. Gynecol Endocrinol 1997;11(Suppl 1):57-62
27. Gallagher JC, Baylink DJ, Freeman R, et al. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 2001;86:4717-26
28. Reginster JY, Agnusdei D, Gennari C, et al. Association of tibolone and fluoride displays a pronounced effect on bone mineral density in postmenopausal osteoporotic women. Gynecol Endocrinol 1999;13:361-8
29. Volker W, Coelingh Bennink HJ, Helmond FA. Effects of tibolone on the endometrium. Climacteric 2001;4:203-8
30. Rymer J, Fogelman I, Chapman MG. The incidence of vaginal bleeding with tibolone treatment. Br J Obstet Gynaecol 1994;101:53-6
31. Gompel A, Siromachkova M, Lombet A, et al. Tibolone actions on normal and breast cancer cells. Eur J Cancer 2000;36(Suppl 4):S76-7
32. Colacurci N, Fornaro F, De Franciscis P, et al. Effects of different types of hormone replacement therapy on mammographic density. Maturitas 2001;40:159-64
33. Lundstrom E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186:717-22
34. Egarter C, Eppel W, Vogel S, et al. A pilot study of hormone replacement therapy with tibolone in women with mastopathic breasts. Maturitas 2001;40:165-71